Want to track ZLAB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 80 days
Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025
Zai Lab Limited leverages global partnerships to commercialize approved therapies in China, focusing on oncology, autoimmune, infectious, and neurological conditions. ZLAB's leading products include VYVGART, AUGTYRO (Repotrectinib), and XACDURO, with VYVGART contributing significantly to Q2 2024 revenues. ZLAB is also developing wholly-owned IP, including ZL-1310 and ZL-1218, which could extend its global footprint beyond China.
Seekingalpha | 1 year ago
Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem
It's not often that a genuine hidden-gem candidate appears in the market. But that label might apply to Chinese biotechnology firm Zai Lab (NASDAQ: ZLAB ).
Investorplace | 1 year ago
2025 © Marketlog. All Rights Reserved.
